Caerin 1.1 and 1.9 peptides halt B16 melanoma metastatic tumours via expanding cDC1 and reprogramming tumour macrophages

Caerin 1.1 and 1.9 peptides halt B16 melanoma metastatic tumours via expanding cDC1 and reprogramming tumour macrophages

Abstract Background Cancer immunotherapy, particularly immune checkpoint inhibitors (ICBs) such as anti-PD-1 antibodies, has revolutionised cancer treatment, although response rates vary among patients. Previous studies have demonstrated that caerin 1.1 and 1.9, host-defence peptides from the Austra...

Celý popis

Podrobná bibliografie
Hlavní autoři: Quanlan Fu, Yuandong Luo, Junjie Li, Hejie Li, Xiaosong Liu, Zhu Chen, Guoying Ni, Tianfang Wang
Médium: Článek
Jazyk:English
Vydáno: BMC 2024-10-01
Edice:Journal of Translational Medicine
Témata:
Caerin peptide
B16 cell
Melanoma
Macrophage
cDC1
CD4+CD8+ T cell
On-line přístup:https://doi.org/10.1186/s12967-024-05763-x

Internet

https://doi.org/10.1186/s12967-024-05763-x

Podobné jednotky